Technology
Health
Biotechnology

Chimerix

$2.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Chimerix and other stocks, options, ETFs, and crypto commission-free!

About

Chimerix, Inc. Common Stock, also called Chimerix, is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Read More Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Employees
59
Headquarters
Durham, North Carolina
Founded
2000
Market Cap
101.47M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
244.77K
High Today
$2.02
Low Today
$1.92
Open Price
$2.00
Volume
307.06K
52 Week High
$5.48
52 Week Low
$1.74

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2013 IPO
US
North America

News

Simply Wall StMar 7

Some Chimerix Shareholders Have Taken A Painful 93% Share Price Drop

Long term investing works well, but it doesn’t always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Chimerix, Inc. (NASDAQ:CMRX) for five years would be nursing their metaphorical wounds since the share price dropped 93% in that time. And it’s not just long term holders hurting, because the stock is down 66% in the last year. Shareholders have had an even rougher run lately, with the share price down 43% in the last 90 days. This could be r...

112
MarketBeatFeb 24

Stock Price, News, & Analysis for Chimerix

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a ...

3

Earnings

-$0.47
-$0.41
-$0.35
-$0.29
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.